FGF21 and metabolic dysfunction-associated steatotic liver disease: These findings underscore the combined influence of elevated circulating FGF21 concentrations and ketone bodies on the increased risk of MASLD and all-cause mortality, suggesting that these biomarkers may serve as integrated indicators for metabolic risk and potential targets for further investigation.